Valuation: Vectura Group

Market Cap 1B 879M 808M 753M 1.43B 95.82B 1.45B 9.72B 3.76B 46.68B 3.77B 3.69B 162B P/E 2019
-27.3x
P/E 2020 6.2x
Enterprise Value 930M 814M 748M 697M 1.32B 88.72B 1.34B 9B 3.49B 43.22B 3.49B 3.42B 150B EV / Sales 2019
2.8x
EV / Sales 2020 3.49x
Free-Float
-
Yield 2019 *
-
Yield 2020 -
25-10-30 Liquidia Technologies, Inc. Enters into an Exclusive Licensing Agreement with Vectura Limited CI
24-09-16 Molex Asia Holdings Ltd. signed an agreement to acquire Vectura Group plc from Vectura Fertin Pharma, Inc. for £300 million. CI
24-04-16 Mundipharma and Vectura Announce Plans to Reformulate Fluticasone Propionate/Formoterol Fumarate CI
21-12-28 EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation CI
21-12-03 Philip Morris CEO does not need M&A to hit smoke free goals RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION" RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION RE
21-12-02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION" RE
5 years 135.4
Extreme 135.4
176
10 years 59.1
Extreme 59.1
180.88
Manager TitleAgeSince
Chief Executive Officer - -
Chief Tech/Sci/R&D Officer - 2016-05-31
Corporate Secretary - 2025-06-29
Director TitleAgeSince
Director/Board Member 53 2023-09-14
Director/Board Member 57 2025-06-29
Date Insider Type Main position Quantity % Market Cap.
21-09-30Fiscal year

Chief Executive Officer

1,311,395 0.2149%
21-09-30Fiscal year 159,896 0.0262%
21-09-30Fiscal year 1,928,114 0.3160%

Financials

2019 2020
Net sales 178M 156M 143M 134M 253M 17.01B 258M 1.73B 668M 8.29B 669M 655M 28.76B 191M 167M 153M 143M 270M 18.18B 275M 1.84B 714M 8.86B 715M 700M 30.74B
Net income -22.1M -19.34M -17.77M -16.56M -31.35M -2.11B -31.94M -214M -82.82M -1.03B -82.95M -81.17M -3.56B 122M 107M 98.41M 91.74M 174M 11.67B 177M 1.18B 459M 5.69B 459M 450M 19.74B
Net Debt -66.5M -58.19M -53.47M -49.84M -94.33M -6.34B -96.12M -643M -249M -3.09B -250M -244M -10.73B -74.4M -65.11M -59.82M -55.76M -106M -7.1B -108M -720M -279M -3.46B -279M -273M -12B
Logo Vectura Group
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.
Employees
-
Sector
-